Illumina (NASDAQ:ILMN) Downgraded by Argus to Hold

Illumina (NASDAQ:ILMNGet Rating) was downgraded by stock analysts at Argus from a “buy” rating to a “hold” rating in a research note issued on Wednesday, The Fly reports.

Several other equities analysts also recently commented on ILMN. Robert W. Baird dropped their price objective on shares of Illumina from $215.00 to $210.00 in a research note on Friday, November 4th. SVB Leerink raised Illumina from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $220.00 to $270.00 in a report on Tuesday, October 4th. Credit Suisse Group cut their price target on Illumina from $230.00 to $225.00 and set a “neutral” rating on the stock in a research note on Friday, November 4th. Piper Sandler dropped their price objective on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a report on Monday, November 14th. Finally, Canaccord Genuity Group dropped their price target on shares of Illumina from $340.00 to $330.00 and set a “buy” rating for the company in a research note on Friday, November 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $252.84.

Illumina Trading Down 0.6 %

Shares of ILMN stock opened at $215.15 on Wednesday. Illumina has a fifty-two week low of $173.45 and a fifty-two week high of $371.16. The stock’s fifty day moving average price is $206.96 and its two-hundred day moving average price is $207.91. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.72 and a current ratio of 0.93. The company has a market cap of $33.84 billion, a PE ratio of -8.15 and a beta of 1.14.

Illumina (NASDAQ:ILMNGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The life sciences company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.05. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a positive return on equity of 4.36% and a negative net margin of 88.40%. Equities analysts predict that Illumina will post 2.23 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $204.58, for a total transaction of $102,290.00. Following the transaction, the senior vice president now directly owns 38,662 shares of the company’s stock, valued at $7,909,471.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction on Friday, January 6th. The stock was sold at an average price of $204.58, for a total transaction of $102,290.00. Following the completion of the sale, the senior vice president now owns 38,662 shares in the company, valued at $7,909,471.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Aimee L. Hoyt sold 871 shares of the company’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $205.57, for a total value of $179,051.47. Following the sale, the senior vice president now owns 2,796 shares of the company’s stock, valued at approximately $574,773.72. The disclosure for this sale can be found here. Insiders have sold 2,371 shares of company stock valued at $499,481 over the last ninety days. 0.13% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

Institutional investors have recently bought and sold shares of the stock. Private Trust Co. NA bought a new stake in Illumina during the second quarter worth $25,000. Glassman Wealth Services grew its stake in Illumina by 72.9% in the 2nd quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 62 shares during the period. Zions Bancorporation N.A. grew its stake in Illumina by 97.6% in the 3rd quarter. Zions Bancorporation N.A. now owns 164 shares of the life sciences company’s stock valued at $31,000 after purchasing an additional 81 shares during the period. Guardian Wealth Advisors LLC bought a new position in Illumina in the 3rd quarter valued at $33,000. Finally, Massmutual Trust Co. FSB ADV grew its stake in Illumina by 50.0% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock valued at $35,000 after purchasing an additional 61 shares during the period. Institutional investors own 87.97% of the company’s stock.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

See Also

The Fly logo

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.